Statins and preeclampsia: An update from the Working Group on Hypertension in Women, Argentine Society of Hypertension.

Source: PubMed, NCBI / U.S. National Library of Medicine

Hypertensive disorders of pregnancy (HDP) affect 5-10% of pregnancies. Preeclampsia (PE) is a severe complication of HDP, associated with high maternal, fetal, and neonatal morbidity and mortality. The pathophysiology of PE involves endothelial dysfunction, vasoconstriction, and impaired placental perfusion, leading to systemic inflammation and multi-organ dysfunction. It has been suggested that statins, traditionally contraindicated during pregnancy, could play a role in this context. Some studies propose that pravastatin, a hydrophilic statin, may not have the same teratogenic effects as lipophilic statins, potentially improving maternal vascular status and significantly reducing the risk of PE. Considering this, the Working Group on Hypertension in Women of the Argentine Society of Hypertension undertook a review of the topic and its current implications.